Apixaban and dalteparin in active malignancy‐associated venous thromboembolism: The ADAM VTE trial

Background Low‐molecular‐weight heparin is the guideline‐endorsed treatment for cancer‐associated venous thromboembolism (VTE). While apixaban is approved for the treatment of acute VTE, limited data support its use in cancer patients. Objectives The primary outcome was major bleeding. Secondary out...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of thrombosis and haemostasis Ročník 18; číslo 2; s. 411 - 421
Hlavní autori:	McBane, Robert D., Wysokinski, Waldemar E., Le‐Rademacher, Jennifer G., Zemla, Tyler, Ashrani, Aneel, Tafur, Alfonso, Perepu, Usha, Anderson, Daniel, Gundabolu, Krishna, Kuzma, Charles, Perez Botero, Juliana, Leon Ferre, Roberto A., Henkin, Stanislav, Lenz, Charles J., Houghton, Damon E., Vishnu, Prakash, Loprinzi, Charles L.
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	England Elsevier Limited 01.02.2020
Predmet:	Anticoagulants Anticoagulants - adverse effects apixaban Bleeding Cancer Chemotherapy dalteparin Dalteparin - adverse effects Heparin Humans Malignancy Metastases Neoplasm Recurrence, Local Pyrazoles Pyridones Thromboembolism Treatment Outcome venous thromboembolism Venous Thromboembolism - diagnosis Venous Thromboembolism - drug therapy cancer bleeding apixaban venous thromboembolism dalteparin
ISSN:	1538-7933, 1538-7836, 1538-7836
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Buďte prvý, kto okomentuje tento záznam!